Barely Significant
← all excerpts

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1).

Cancers (Basel) · 2020 · PMC7072500 · PMID 32013055

Europe PMCDOI
1
hedged sentence
0.0550
closest p · 1.1× alpha
0.0550
boldest claim

The sentences

borderline significantp = 0.055so close (0.05 < p ≤ 0.1)
Furthermore, a borderline significant interaction between maintenance treatment and HDT ( p = 0.055) was observed. 2.4.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.